To cite this paper use one of the standards below:
Photobiomodulation (PBM) is a non-invasive approach that promotes molecular, cellular, and systemic effects, such as enhanced ATP synthesis, cell proliferation, and tissue repair. In cancer, however, its use is controversial due to concerns that it may promote tumor cell proliferation. Breast cancer is the leading cause of cancer-related deaths among women worldwide, with p53 mutations playing a key role in tumor progression. The p53 protein is a tumor suppressor, involved in cell cycle arrest, DNA repair, and apoptosis. Mutations in this gene impair its function contributing to cancer development. Although PBM has been explored for reducing amyloidogenic proteins in neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, its impacts on protein aggregation in cancer is still unclear. Therefore, we evaluated whether low-power infrared laser irradiation (808 nm; 20 and 200 J/cm²) affects p53 aggregation in MDA-MB-231 breast cancer cells. To our knowledge, this is one of the first studies to explore the effect of PBM on protein aggregation in a cancer model. Cells were irradiated and incubated for 24 and 48 hours, with non-irradiated cells as controls. Protein aggregation was assessed by dot blot and western blot, while p53 localization was analyzed by immunofluorescence. Cell viability was measured by LDH release. Preliminary results suggest that infrared LLLT does not alter the quantity of p53 by dot blot and western blot assays, or modulate the nuclear aggregates localization of mutant p53 R280K at either fluence or time point. Additionally, no changes in cell viability were observed. Our findings demonstrate that low-level infrared laser irradiation (808 nm, 20 and 200 J/cm²) does not induce cytotoxic effects or modulate the expression or aggregation of mutant p53 in MDA-MB-231 breast cancer cells at 24- and 48-hours post-treatment. These results suggest that, under the tested conditions, a PBM does not affect mutant p53 behavior or compromise cell integrity, supporting its safety in breast cancer models harboring TP53 mutations. However, further studies using additional cell lines, functional assays, and in vivo models are needed to better understand the biological effects and therapeutic potential of photobiomodulation in oncology.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper